Does normalisation of biochemical markers of bone formation correlate with clinical benefit from therapy in metastatic breast cancer?
Clinical benefit from systemic therapy was primarily accompanied by a normalization of biochemical markers representing bone formation. This result reflects the physiology of the "bone remodeling unit". In patients without this normalization, thorough and early restaging is warranted since the systemic therapy may be ineffective.
Administration of G-CSF and SCF in the subacute phase after focal cerebral ischemia is effective for functional recovery, enhancing cytokine-induced generation of neuronal cells from both BM-derived cells and intrinsic neural stem/progenitor cells. Because G-CSF and SCF are available for clinical use, these findings suggest a new therapeutic strategy for stroke.